Barbara Yanni

Director/Board Member presso TREVENA, INC.

Patrimonio netto: 131 558 $ in data 31/03/2024

69 anni

Health Technology

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Carrie Bourdow	F	61	TREVENA, INC.	9 anni
Craig Jalbert	M	63	ONCORUS, INC.	1 anni
Maurice Zauderer	M	78	VACCINEXPAR	27 anni
Sijmen de Vries	M	65	PHARMING GROUP N.V.	16 anni
Joel S. Solomon	M	-	TREVENA, INC.	9 anni
Emmanuel Huynh	M	54	ABIONYX PHARMA	5 anni
Deborah Jorn	F	66	PHARMING GROUP N.V.	5 anni
Tom Glocer	M	63	MERCK & CO., INC.	17 anni
Jacob Frieberg	M	67	VACCINEXPAR	9 anni
Chirfi Guindo	M	58	MERCK & CO., INC.	13 anni
Robert Young	M	-	Mesentech, Inc. Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada.	-
Robert Yoder	M	59	TREVENA, INC.	6 anni
Barry Shin	M	52	TREVENA, INC.	5 anni
Michael Underhill	M	-	Mesentech, Inc. Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada.	-
Mireille Sanders	F	56	PHARMING GROUP N.V.	5 anni
Marvin Johnson	M	61	TREVENA, INC.	3 anni
Todd L. Wandstrat	M	-	TREVENA, INC.	3 anni
Elizabeth Evans	M	52	VACCINEXPAR	23 anni
Angela Bagley	F	-	TREVENA, INC.	3 anni
Ruud van Outersterp	M	60	PHARMING GROUP N.V.	4 anni
Bala S. Manian	M	77	VACCINEXPAR	20 anni
Anne Phillips	M	70	TREVENA, INC.	10 anni
Chrystyna Stecyk	F	61	VACCINEXPAR	4 anni
Michael Levitan	M	66	PHARMING GROUP N.V.	-
Peter Wendell	M	73	MERCK & CO., INC.	21 anni
Albert Friedberg	M	77	VACCINEXPAR	27 anni
Leonard Kruimer	M	66	PHARMING GROUP N.V.	3 anni
Jake Nunn	M	54	TREVENA, INC.	11 anni
Scott Braunstein	M	60	TREVENA, INC.	6 anni
Dalton Smart	M	58	MERCK & CO., INC.	15 anni
Gerald van Strydonck	M	79	VACCINEXPAR	21 anni
Richard Peters	M	61	PHARMING GROUP N.V.	1 anni
Allan Gabor	M	-	MERCK & CO., INC.	11 anni
Peter Savas	M	75	Mesentech, Inc. Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada.	-
Anurag Relan	M	52	PHARMING GROUP N.V.	-
Patricia Drake	F	-	TREVENA, INC.	3 anni
John Leonard	M	77	VACCINEXPAR	-
Mark Pykett	M	60	PHARMING GROUP N.V.	4 anni
Stephen Toor	M	52	PHARMING GROUP N.V.	4 anni
Ernie Smith	M	52	VACCINEXPAR	23 anni
Mark Corrigan	M	66	TREVENA, INC.	1 anni
Jay Mohr	M	-	Mesentech, Inc. Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada.	4 anni
Jocelyn Jackson	F	-	Symic Bio, Inc. Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.	5 anni
Grace Wong-Sarad	F	-	Symic Bio, Inc. Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.	9 anni
Jonathan Polak	M	-	Mesentech, Inc. Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada.	-
Jeroen Wakkerman	M	55	PHARMING GROUP N.V.	4 anni
Mark Demitrack	M	66	TREVENA, INC.	6 anni
Pamela Eisele	F	-	MERCK & CO., INC.	15 anni
Jabine T. M. van der Meijs	M	58	PHARMING GROUP N.V.	3 anni
William Newell	M	66	Symic Bio, Inc. Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.	9 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Richard Kogan	M	81	MERCK & CO., INC.	21 anni
Brian Shea	M	36	ONCORUS, INC.	2 anni
John McCabe	M	55	ONCORUS, INC.	3 anni
Maxine Gowen	M	66	TREVENA, INC.	14 anni
Richard Clark	M	77	MERCK & CO., INC.	6 anni
Jonathan Violin	M	49	TREVENA, INC.	11 anni
Lonnie Moulder	M	66	TREVENA, INC.	12 anni
John M. Limongelli	M	54	TREVENA, INC.	5 anni
Fred Hassan	M	78	MERCK & CO., INC.	6 anni
Roberto Cuca	M	57	TREVENA, INC.	5 anni
Robert Dolski	M	54	AKCEA THERAPEUTICS, INC.	1 anni
Richard Pasternak	M	75	MERCK & CO., INC. ABIONYX PHARMA	4 anni
Scott Applebaum	M	57	TREVENA, INC.	1 anni
Paul Sekhri	M	65	PHARMING GROUP N.V.	8 anni
Luke Evnin	M	60	ONCORUS, INC.	7 anni
Alexander Nolte	M	52	ONCORUS, INC.	-
Larry G. Edwards	M	52	MERCK & CO., INC.	15 anni
Anne-Marie de Groot	F	43	PHARMING GROUP N.V.	7 anni
Aad de Winter	M	71	PHARMING GROUP N.V.	12 anni
Stephen Harbin	M	66	ONCORUS, INC.	3 anni
Michael Davidson	M	67	ABIONYX PHARMA	4 anni
Linda C. Wase	M	-	TREVENA, INC.	-
Michael Nally	M	48	MERCK & CO., INC.	10 anni
Kimberly Park	F	60	MERCK & CO., INC.	13 anni
John Goldberg	M	51	ONCORUS, INC.	5 anni
Craig Thompson	M	71	MERCK & CO., INC.	10 anni
Kenneth F. Bartizal	M	72	MERCK & CO., INC.	20 anni
Michael MacLean	M	58	AKCEA THERAPEUTICS, INC.	3 anni
Michael Dougherty	M	66	TREVENA, INC.	10 anni
Julie Gerberding	M	69	MERCK & CO., INC.	-
Chris Mirabelli	M	69	TREVENA, INC.	6 anni
Rochelle Lazarus	F	76	MERCK & CO., INC.	16 anni
Carlos Eduardo Represas de Almeida	M	78	MERCK & CO., INC.	-
Leslie Brun	M	72	MERCK & CO., INC.	13 anni
Edward Fitzgerald	M	68	AKCEA THERAPEUTICS, INC.	3 anni
Francois Nader	M	67	TREVENA, INC.	1 anni
Solomon David	M	57	TREVENA, INC.	1 anni
Brett Monia	M	62	AKCEA THERAPEUTICS, INC.	-
Wendell Weeks	M	64	MERCK & CO., INC.	16 anni
William N. Kelley	M	84	MERCK & CO., INC.	-
Mary Fenton	F	60	ONCORUS, INC.	4 anni
Terry McGuire	M	68	TREVENA, INC.	6 anni
Elaine Hochberg	F	67	AKCEA THERAPEUTICS, INC.	3 anni
B. Parshall	F	70	AKCEA THERAPEUTICS, INC.	5 anni
John Barrie Ward	M	86	PHARMING GROUP N.V.	14 anni
Thomas Shenk	M	77	MERCK & CO., INC.	11 anni
Sandy Smith	M	77	AKCEA THERAPEUTICS, INC.	3 anni
Thomas Robert Cech	M	76	MERCK & CO., INC.	-
Elizabeth Hougen	F	62	AKCEA THERAPEUTICS, INC.	-
Wendy Yarno	F	69	MERCK & CO., INC.	9 anni

Statistiche

Paese	Relazioni	% del totale
Stati Uniti	77	77.00%
Paesi Bassi	16	16.00%
Canada	5	5.00%
Francia	3	3.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni